In one paragraphArticle in Epigenomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
22 authors.
Valentina S ObrezanenkoFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks», Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 123182, Russia.ORCID 0000-0002-7449-255X Polina M ShulgaFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks», Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 123182, Russia.
Anastasia G VolkovaFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks», Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 123182, Russia.ORCID 0000-0003-2853-9529 Anastasia A PrimovaFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks», Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 123182, Russia.ORCID 0000-0003-0118-529X Yulia A RemizovaFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks», Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 123182, Russia.
Ivan O MeshkovFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks», Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 123182, Russia.ORCID 0000-0002-7358-6108 Alexandra D KikotFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks», Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 123182, Russia.
Daria A TarasovaFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks», Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 123182, Russia.
Ekaterina S BolashovaFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks», Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 123182, Russia.
Alexey A IvashechkinFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks», Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 123182, Russia.ORCID 0000-0002-0148-1112 Antonida V MakhotenkoFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks», Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 123182, Russia.ORCID 0000-0002-7894-9422 Ekaterina A SnigirFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks», Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 123182, Russia.ORCID 0000-0003-1245-7764 Yulia A MasyukovaFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks», Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 123182, Russia.
Elizaveta I RadionFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks», Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 123182, Russia.ORCID 0000-0003-3225-434X Olesya A KuznetsovaFederal State Budgetary Institution "NN Blokhin National Medical Research Center of Oncology", Ministry of Health of the Russian Federation (NN Blokhin NMRCO), Moscow 115478, Russia.ORCID 0000-0001-7753-3081 Maria S CheporovaFederal State Budgetary Institution "NN Blokhin National Medical Research Center of Oncology", Ministry of Health of the Russian Federation (NN Blokhin NMRCO), Moscow 115478, Russia.ORCID 0009-0003-7514-5220 Michail Y FedyaninFederal State Budgetary Institution "NN Blokhin National Medical Research Center of Oncology", Ministry of Health of the Russian Federation (NN Blokhin NMRCO), Moscow 115478, Russia.ORCID 0000-0001-5615-7806 Alexey A TryakinFederal State Budgetary Institution "NN Blokhin National Medical Research Center of Oncology", Ministry of Health of the Russian Federation (NN Blokhin NMRCO), Moscow 115478, Russia.ORCID 0000-0003-2245-214X Valentin V MakarovFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks», Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 123182, Russia.ORCID 0000-0001-9495-0266 Vladimir S YudinFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks», Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 123182, Russia.ORCID 0000-0002-9199-6258 Anton A KeskinovFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks», Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 123182, Russia.ORCID 0000-0001-7378-983X Anna S MakarovaFederal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks», Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency), Moscow 123182, Russia.ORCID 0000-0002-9711-9256 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
backgroundHML-2 subgroup mobile genetic elements of the HERV-K family were described to participate in carcinogenesis processes, but their expression and epigenetic regulation in molecular subtypes of colorectal cancer (CRC) remain partly characterized. The present study aimed to evaluate the expression of HML-2 elements using RNA-sequencing data in paired tumor and normal intestinal tissue samples from 63 patients with CRC to identify patterns of the retrotransposons' activity in different molecular subtypes (CMSs).
methodsRNA-sequencing and DNA methylation data were analyzed for paired CRC and normal tissue samples. HERV-K expression was assessed using three bioinformatics tools: Telescope (version 1.0.3), TEtranscripts (version 2.2.3), GeneTEFlow (version 2020). Molecular tumor subtypes were defined using the CMScaller (version 0.99.2) program. The results of the HML-2 loci expression analysis were supplemented with the HML-2 proteins expression data obtained by quantitative RT-PCR.
resultsHML-2 expression assessment by GeneTEFlow (version 2020), TECount (version 2.2.3) and Telescope (version 1.0.3) showed high convergence: the Pearson correlation coefficient for each tool exceeded 0.88. Several HML-2 loci were identified as differentially expressed in CRC samples of different CMS. The PCR results confirmed an increase in HML-2 expression in tumor tissues. For all CMSs, an inverse association was detected between differential methylation of CpG sites and differential expression of HML-2 loci. Associations of HML-2 expressions with differentially expressed genes in which they are located were found, and for a number of such genes an inverse relationship between the expression level and the methylation level of their promoters were demonstrated, and data on the involvement in the pathogenesis of CRC were described:
conclusionsAnalysis of the expression of HML-2 and its association with CpG methylation contributes to a comprehensive interpretation of the CRC pathogenesis mechanisms.
Indexed as
CMScolorectal cancerDNA methylationHERV-K (HML-2)RNA-seqviral mimicry
Identifiers
PMID41718409
PMCPMC12922068
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390